QURE · uniQure N.V.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. uniQure reported Q2 2026 with confirmed AMT-130 BLA and U.K. MAA submissions on track for Q3 2026, FDA alignment on accelerated approval using three-year data, four-year data readout expected in September, strengthened cash position to $810.3M (runway into 2030) via a $259M follow-on offering, but net loss widened to $81.1M from $37.7M year-over-year.
- + FDA confirmed AMT-130 BLA submission under accelerated approval pathway is reasonable based on three-year data
- + Four-year AMT-130 data readout planned for September 2026
- + Balance sheet strengthened by $259M follow-on offering, extending cash runway into 2030
- + AMT-260 epilepsy program showed early biological activity with 3 of 6 low-dose patients achieving 79%-100% seizure reductions
- − Net loss widened to $81.1M from $37.7M year-over-year
- − Other non-operating items shifted to a $27.0M expense from a $6.6M gain, including $16.0M loss from pre-funded warrant fair value changes and $20.4M unfavorable FX swing
- − AMT-191 Fabry program dosing paused in mid- and high-dose cohorts after Grade 3 liver enzyme elevations deemed dose-limiting toxicities
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QURE
this stock
uniQure N.V.
|
$2.41B | +1.0% | -47.8% | — | 15.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QURE | -43.5% | -49.5% | +48.2% | -50.4% | +1.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -42.8% | -49.6% | +36.1% | -49.8% | -10.9% |